Review





Similar Products

93
TargetMol smi 4a
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Smi 4a, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/(Z)-SMI-4a/pmc12248293-212-6-24
Average 93 stars, based on 1 article reviews
smi 4a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
MedChemExpress smi 4a
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Smi 4a, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pmc11993190-279-36-37
Average 93 stars, based on 1 article reviews
smi 4a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Kuang Lung Shing smi 4a
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Smi 4a, supplied by Kuang Lung Shing, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/4a+smi/pm40882409-247-22-15
Average 86 stars, based on 1 article reviews
smi 4a - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

93
Selleck Chemicals vivo smi4a treatment models
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Vivo Smi4a Treatment Models, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pm38700370-56-2-29
Average 93 stars, based on 1 article reviews
vivo smi4a treatment models - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Selleck Chemicals smi4a
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Smi4a, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pm38700370-56-28-29
Average 93 stars, based on 1 article reviews
smi4a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
MedChemExpress pim kinase inhibitors
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Pim Kinase Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pm38869285-247-0-8
Average 93 stars, based on 1 article reviews
pim kinase inhibitors - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Selleck Chemicals tcs pim
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Tcs Pim, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pm38869285-247-3-19
Average 93 stars, based on 1 article reviews
tcs pim - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
MedChemExpress tcs pim
( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 <t>μM),</t> <t>SMI-4a</t> (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.
Tcs Pim, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/smi+4a/SMI-4a/pm38869285-247-3-8
Average 93 stars, based on 1 article reviews
tcs pim - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 μM), SMI-4a (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.

Journal: Science Advances

Article Title: BRD4770 protects against DOX-induced cardiotoxicity by inhibiting apoptosis and ferroptosis

doi: 10.1126/sciadv.adw1720

Figure Lengend Snippet: ( A ) Schematic of cell-based high-throughput screening of epigenetic compounds for protection against DOX/erastin-induced cardiomyocyte death. ( B ) The scatter plot of the effect of epigenetic compounds on DOX (top)– or erastin (bottom)–induced cardiomyocyte death. ( C ) Venn analysis of a drug compound. The top 25 compounds that protect against DOX- or erastin-induced cardiomyocyte death were selected separately, overlapping a total of 8 compounds. ( D ) The eight compounds that protect against both DOX- and erastin-induced cardiomyocyte death. Red indicates compounds that have been studied, and green indicates compounds that have not yet been reported in DIC. BDNF, brain-derived neurotrophic factor; JNK1, c-Jun N-terminal kinase 1; TrkA, tropomyosin receptor kinase A; Pim1, proviral integration site for Moloney murine leukemia virus-1 (Pim1) kinase; EGFR, epidermal growth factor receptor; PKA, cAMP-dependent protein kinase; PKC, protein kinase C; HDAC1, histone deacetylase 1. ( E ) The effects of J147 (5 μM), BRD4770 (5 μM), SCR7 pyrazine (5 μM), SMI-4a (5 μM), daphnetin (5 μM), BG45 (5 μM), and entinostat (5 μM) on cell viability in H9C2 cells after 24 hours of DOX or erastin treatment ( n = 6). Statistical significance was determined using (E) one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons. * P < 0.05 and ** P < 0.01.

Article Snippet: BRD4770 (#T1923), J147 (#T1993), BG45 (#T2294), SMI-4a (#T3058), daphnetin (#T2851), entinostat (#T6233), ISRIB (#T2027), OTS186935 (# T12344 ), and UNC0638 (#T3257) were purchased from TargetMol (Wellesley Hills, MA, USA).

Techniques: High Throughput Screening Assay, Derivative Assay, Virus, Histone Deacetylase Assay